Orchestra Biomed Holdings, Inc. (OBIO)
NASDAQ:OBIO
Want to see OBIO full AI Analyst Report?
Top Page
Orchestra BioMed Holdings
(NASDAQ:OBIO)
Select Model
Select Model
Rating:41Neutral
Price Target:
$4.00
▼(-12.66% Downside)
Action:Reiterated
Date:05/16/26
OBIO scores low primarily due to sustained unprofitability and significant ongoing cash burn, which raise financing risk despite low leverage. Technicals are also weak with the stock trading below major moving averages and a negative MACD. Valuation provides little support because earnings are negative and no dividend yield is available.
Positive Factors
Low Leverage / Strong Asset Base
The company's very low debt (debt-to-equity ~0.04) and sizable asset base provide durable financial flexibility to fund clinical programs or absorb near-term setbacks. This balance-sheet strength reduces immediate refinancing pressure and supports R&D investments while management pursues commercialization paths.
Negative Factors
Persistent Cash Burn
Sustained negative operating and free cash flows of roughly -$54M to -$55M TTM indicate the company is consuming significant cash to fund operations and development. This persistent burn creates ongoing financing risk, increasing likelihood of dilution or the need for partner/licensing deals to fund programs.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage / Strong Asset Base
The company's very low debt (debt-to-equity ~0.04) and sizable asset base provide durable financial flexibility to fund clinical programs or absorb near-term setbacks. This balance-sheet strength reduces immediate refinancing pressure and supports R&D investments while management pursues commercialization paths.
Read all positive factors
Orchestra BioMed Holdings (OBIO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$238.92M
Dividend YieldN/A
Average Volume (3M)258.58K
Price to Earnings (P/E)―
Beta (1Y)1.89
Revenue Growth1033.89%
EPS Growth36.35%
CountryUS
Employees70
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.42
Shares Outstanding59,880,714
10 Day Avg. Volume266,593
30 Day Avg. Volume258,580
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)2.51
Price to Sales (P/S)4.76
P/FCF Ratio-3.22
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue7.24
Enterprise Value/Gross Profit7.30
Enterprise Value/Ebitda-4.50
Forecast
1Y Price Target
$11.40Price Target Upside148.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.56
Revenue Forecast (FY)$545.43K
Orchestra BioMed Holdings Business Overview & Revenue Model
Company Description
Orchestra BioMed Holdings, Inc. operates as an innovative company in the biomedical sector. Its leading product candidates are BackBeat Cardiac Neuromodulation Therapy (CNT), designed to manage hypertension, and the Virtue Sirolimus AngioInfusion ...
How the Company Makes Money
null...
Orchestra BioMed Holdings Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
68
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 32.72M | 33.48M | 2.64M | 2.76M | 3.53M | -782.00K |
| Gross Profit | 32.49M | 33.29M | 2.43M | 2.57M | 3.21M | -981.00K |
| EBITDA | -52.72M | -51.23M | -60.72M | -48.83M | -33.39M | -21.91M |
| Net Income | -54.64M | -52.70M | -61.02M | -49.12M | -33.61M | -23.01M |
Balance Sheet | ||||||
| Total Assets | 100.66M | 114.86M | 76.17M | 95.21M | 95.57M | 13.53M |
| Cash, Cash Equivalents and Short-Term Investments | 94.40M | 106.51M | 66.81M | 87.59M | 83.78M | 10.90M |
| Total Debt | 33.63M | 1.69M | 16.53M | 1.69M | 11.87M | 5.67M |
| Total Liabilities | 49.69M | 51.48M | 43.22M | 27.17M | 43.04M | 84.76M |
| Stockholders Equity | 50.97M | 63.38M | 32.96M | 68.04M | 52.53M | -71.23M |
Cash Flow | ||||||
| Free Cash Flow | -55.08M | -49.45M | -50.85M | -46.20M | -29.88M | -19.70M |
| Operating Cash Flow | -54.52M | -48.96M | -50.56M | -46.13M | -29.29M | -19.43M |
| Investing Cash Flow | -29.62M | -26.94M | 13.09M | 10.69M | -64.12M | 13.02M |
| Financing Cash Flow | 94.16M | 88.33M | 29.17M | 46.22M | 103.26M | -3.99M |
Orchestra BioMed Holdings Technical Analysis
Positive
4.58
Price Trends
4.06
Negative
4.14
Negative
3.97
Positive
Market Momentum
-0.02
Negative
50.10
Neutral
25.20
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OBIO, the sentiment is Positive. The current price of 4.58 is above the 20-day moving average (MA) of 3.97, above the 50-day MA of 4.06, and above the 200-day MA of 3.97, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 50.10 is Neutral, neither overbought nor oversold. The STOCH value of 25.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for OBIO.
Orchestra BioMed Holdings Risk Analysis
Orchestra BioMed Holdings disclosed 81 risk factors in its most recent earnings report. Orchestra BioMed Holdings reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Orchestra BioMed Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $129.77M | -6.61 | -72.68% | ― | ― | 64.57% | |
55 Neutral | $655.66M | -14.79 | -31.46% | ― | ― | 67.20% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $128.61M | -1.58 | -135.60% | ― | ― | 17.43% | |
46 Neutral | $82.73M | -1.85 | -95.50% | ― | -10.71% | 28.59% | |
41 Neutral | $238.92M | -2.80 | -137.99% | ― | 1033.89% | 36.35% |
* Healthcare Sector Average
OBIO
Orchestra BioMed Holdings
3.99
0.89
28.71%
CRDF
Cardiff Oncology
1.21
-1.95
-61.71%
GLSI
Greenwich LifeSciences
23.38
14.62
166.89%
CLYM
Climb Bio
11.45
10.25
854.17%
CGTX
Cognition Therapeutics
1.45
1.19
457.69%
PYXS
Pyxis Oncology
2.03
0.82
67.77%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.